Oxazolidinone Antibacterials and Our Experience

Brijesh Kumar Srivastava, R. Soni, Jayendra Z. Patel, Mukul R Jain, P. Patel
{"title":"Oxazolidinone Antibacterials and Our Experience","authors":"Brijesh Kumar Srivastava, R. Soni, Jayendra Z. Patel, Mukul R Jain, P. Patel","doi":"10.2174/187152108785908820","DOIUrl":null,"url":null,"abstract":"The Oxazolidinones are a promising novel chemical synthetic class of antibiotics identified in the last two dec- ades and have been subjected to intensive discovery efforts. They possess impressive antibacterial activity against Gram- positive pathogens. Oxazolidinones act through a unique mechanism of inhibitory bacterial protein biosynthesis. Linezolid (Zyvox TM ) has been the only drug of oxazolidinone class to reach the market after USFDA approval. Here we review our efforts directed to the discovery of novel oxazolidinone antibacterials evolved through structure-activity relationship (SAR) and an overview of contemporary on going efforts.","PeriodicalId":89320,"journal":{"name":"Anti-infective agents in medicinal chemistry","volume":"121 1","pages":"258-280"},"PeriodicalIF":0.0000,"publicationDate":"2008-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/187152108785908820","citationCount":"16","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anti-infective agents in medicinal chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/187152108785908820","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 16

Abstract

The Oxazolidinones are a promising novel chemical synthetic class of antibiotics identified in the last two dec- ades and have been subjected to intensive discovery efforts. They possess impressive antibacterial activity against Gram- positive pathogens. Oxazolidinones act through a unique mechanism of inhibitory bacterial protein biosynthesis. Linezolid (Zyvox TM ) has been the only drug of oxazolidinone class to reach the market after USFDA approval. Here we review our efforts directed to the discovery of novel oxazolidinone antibacterials evolved through structure-activity relationship (SAR) and an overview of contemporary on going efforts.
恶唑烷酮抗菌剂和我们的经验
恶唑烷酮类抗生素是近二十年来发现的一种很有前途的新型化学合成抗生素,经过了大量的发现工作。它们对革兰氏阳性病原体具有令人印象深刻的抗菌活性。恶唑烷酮通过一种独特的机制抑制细菌蛋白质的生物合成。利奈唑胺(Zyvox TM)是唯一获得美国fda批准进入市场的恶唑烷酮类药物。在这里,我们回顾了我们通过结构-活性关系(SAR)发现新型恶唑烷酮类抗菌药物的努力,并概述了当代正在进行的努力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书